Hepo Pharmaceuticals announced that its partner, Solstice Oncology, has successfully raised $225 million in Series A funding to advance the...
-
-
Recent Updates
- US firms in China more upbeat on outlook as profits recover, survey shows
- US firms’ confidence in China has soared amid Xi-Trump trade truce: survey
- TÜV Rheinland Certifies Multiple Robot Products at IFA 2026, Supporting Chinese Companies’ Global Expansion
- Hong Kong Stock Thousand Baidu Releases Impressive Half-Year Report, AI Business Growth Momentum Unleashed
- Solstice Oncology Partner, Hepo Pharmaceuticals, Completes $225 Million Series A Funding to Accelerate Prusabide Monoclonal Antibody in New Adjuvant Cancer Immunotherapy
- Adani Airports to Raise Approximately $1 Billion in Primary Equity from Global Major Investors
- India’s Serious Fraud Office Urges Probe Into Xiaomi’s Business in Country
- SFIO Recommends Investigation Into Xiaomi’s India Business and FDI Compliance
- China’s Tech IPO Market Surges with $32bn Raised in 2026
- Encounter the World, Set Off for Tianjin: 2026 China Culture & Tourism Industries Expo Kicks Off
Blogroll